EGFR and mTOR as therapeutic targets in glioblastoma
EGFR and mTOR as therapeutic targets in glioblastoma |
|
https://doi.org/10.18632/oncotarget.27094
Michael W. Ronellenfitsch,
Anna-Luisa Luger,
and Joachim P. Steinbach
|
| 4721-4723 |
The revolution will be open-source: how 3D bioprinting can change 3D cell culture
The revolution will be open-source: how 3D bioprinting can change 3D cell culture |
|
https://doi.org/10.18632/oncotarget.27099
Robert D. Bruno,
John Reid,
and Patrick C. Sachs
|
| 4724-4726 |
Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives |
|
https://doi.org/10.18632/oncotarget.27107
Jonathan M. Lehman,
and Pierre P. aMassion
|
| 4727-4730 |
Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer
Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer |
|
https://doi.org/10.18632/oncotarget.27089
Sebastian Prill,
Jakob Rebstock,
Anja Tennemann,
Justus Körfer,
Rasmus Sönnichsen,
René Thieme,
Ines Gockel,
Orestis Lyros,
Astrid Monecke,
Christian Wittekind,
Arved Weimann,
Kerstin Grosser,
Volker Wiechmann,
Christoph Kubick,
Ingo Bechmann,
Florian Lordick,
and Sonja Kallendrusch
|
| 4731-4742 |
KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells
KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells |
|
https://doi.org/10.18632/oncotarget.27092
Kengo Okamoto,
Yuji Tanaka,
Sachiko Ogasawara,
Chikashi Obuse,
Jun-ichi Nakayama,
Hirohisa Yano,
and Makoto Tsuneoka
|
| 4743-4760 |
Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles |
|
https://doi.org/10.18632/oncotarget.27109
Matthew S. Strand,
Bradley A. Krasnick,
Hua Pan,
Xiuli Zhang,
Ye Bi,
Candace Brooks,
Christopher Wetzel,
Narendra Sankpal,
Timothy Fleming,
S. Peter Goedegebuure,
David G. DeNardo,
William E. Gillanders,
William G. Hawkins,
Samuel A. Wickline,
and Ryan C. Fields
|
| 4761-4775 |
Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer
Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer |
|
https://doi.org/10.18632/oncotarget.27113
Samuel Rosas,
Ryan T. Hughes,
Michael Farris,
Hwajin Lee,
Emory R. McTyre,
Johannes F. Plate,
Lihong Shi,
Cynthia L. Emory,
A. William Blackstock,
Bethany A. Kerr,
and Jeffrey S. Willey
|
| 4776-4785 |
Genomics applied to the treatment of breast cancer
Genomics applied to the treatment of breast cancer |
|
https://doi.org/10.18632/oncotarget.27102
Diaddin Hamdan,
Thi Thuy Nguyen,
Christophe Leboeuf,
Solveig Meles,
Anne Janin,
and Guilhem Bousquet
|
| 4786-4801 |
Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix |
|
https://doi.org/10.18632/oncotarget.27101
Minakshi Mann,
Sachin Kumar,
Shyam S. Chauhan,
Neerja Bhatla,
Sunesh Kumar,
Sameer Bakhshi,
Ritu Gupta,
Ashok Sharma,
and Lalit Kumar
|
| 4802-4802 |
